{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:55:33Z","timestamp":1760385333773},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,11,6]],"date-time":"2013-11-06T00:00:00Z","timestamp":1383696000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Ertapenem (preferred choice for ESBL-producing organisms) use exhibited an increasing trend from 2006 to 2008. As extensive use of ertapenem might induce the mutation of resistant bacteria strains to ertapenem, we aimed to assess the appropriateness and impact of ertapenem-use, on ESBL production, the trends of gram-negative bacterial resistance and on the utilization of other antibiotics in our institution.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Inpatients who received a dose of ertapenem during 1 January 2006 to 31 December 2008, were reviewed. Pertinent patient clinical data was extracted from the pharmacy databases and assessed for appropriateness based on dose and indication. Relevant data from Network for Antimicrobial Resistance Surveillance (Singapore) (NARSS) was extracted, to cross-correlate with ertapenem via time series to assess its impact on hospital epidemiology, trends of gram-negative resistance and consumption of other antibiotics from 2006 to mid-2010.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>906 cases were reviewed. Ertapenem therapy was appropriate in 72.4% (93.7% success rate). CNS adverse events were noted in 3.2%. Readmission rate (30-day) due to re-infection (same pathogen) was 5.5%. Fifty cases had cultures growing <jats:italic>Pseudomonas aeruginosa<\/jats:italic> within 30 days of ertapenem initiation, with 25 cases growing carbapenem-resistant <jats:italic>Pseudomonas aeruginosa<\/jats:italic>.<\/jats:p>\n            <jats:p>Ertapenem use increased from 0.45 DDD\/100 patient days in 2006 to 1.2 DDD\/100 patient days in mid-2010. Overall, the increasing trend of ertapenem consumption correlated with 1) increasing incidence-densities of ciprofloxacin-resistant\/cephalosporin-resistant <jats:italic>E. coli<\/jats:italic> at zero time lag; 2) increasing incidence-densities of ertapenem-resistant <jats:italic>Escherichia. coli<\/jats:italic> and <jats:italic>Klebsiella spp.<\/jats:italic> at zero time lag; 3) increasing incidence-density of carbapenem-resistant <jats:italic>Pseudomonas aeruginosa<\/jats:italic>, at zero time lag.<\/jats:p>\n            <jats:p>Increasing ertapenem consumption was significantly correlated with decreasing consumption of cefepime (R<jats:sup>2<\/jats:sup> = 0.37344) 3 months later. It was significantly correlated with a decrease in imipenem consumption (R<jats:sup>2<\/jats:sup> = 0.31081), with no time lag but was correlated with subsequent increasing consumption of meropenem (R<jats:sup>2<\/jats:sup> = 0.4092) 6 months later.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Ertapenem use was appropriate. Increasing Ertapenem consumption did not result in a decreasing trend of ESBL producing enterobacteriaceae and could result in the selection for multi-drug resistant bacteria.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2334-13-523","type":"journal-article","created":{"date-parts":[[2013,11,6]],"date-time":"2013-11-06T16:01:28Z","timestamp":1383753688000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of Ertapenem use with Impact Assessment on Extended-Spectrum Beta-Lactamases (ESBL) Production and Gram-Negative resistance in Singapore General Hospital (SGH)"],"prefix":"10.1186","volume":"13","author":[{"given":"Cheryl Li-Ling","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winnie","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda Ling-Chiu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa Ting-Ting","family":"Liew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szu Chin","family":"Nah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choon Nam","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej Piotr","family":"Chlebicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Lay-Hoon","family":"Kwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,6]]},"reference":[{"issue":"4","key":"4207_CR1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","volume":"18","author":"DL Paterson","year":"2005","unstructured":"Paterson DL, Bonomo RA: Extended-spectrum Beta-lactamases: A Clinical Update. Clin Microbiol Rev. 2005, 18 (4): 657-86. 10.1128\/CMR.18.4.657-686.2005.","journal-title":"Clin Microbiol Rev"},{"key":"4207_CR2","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/jac\/dkg404","volume":"52","author":"PM Shah","year":"2003","unstructured":"Shah PM, Isaac RD: Ertapenem, The First of A New Group of Carbapenems. Journal of Antimicrobial Chemotherapy. 2003, 52: 538-542. 10.1093\/jac\/dkg404.","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"4207_CR3","unstructured":"Invanz [package insert]. 2009, Whitehouse Station, N.J: Merck & Co., Inc, http:\/\/www.merck.com\/product\/usa\/pi_circulars\/i\/invanz\/invanz_pi.pdf. Accessed June 1, 2013"},{"issue":"S2","key":"4207_CR4","first-page":"ii23","volume":"53","author":"DE Nix","year":"2004","unstructured":"Nix DE, Majumdar AK, DiNubile MJ: Pharmacokinetics and Pharmacodynamics of Ertapenem: An Overview for Clinicians. Journal of Antimicrobial Chemotherapy. 2004, 53 (S2): ii23-ii28.","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"4207_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/jac\/dki009","volume":"55","author":"DM Livermore","year":"2005","unstructured":"Livermore DM, Mushtaq S, Warner M: Selectivity of Ertapenem for Pseudomonas aeruginosa Mutants Cross-resistant to Other Carbapenems. Journal of Antimicrobial Chemotherapy. 2005, 55: 306-311. 10.1093\/jac\/dki009.","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"405","key":"4207_CR6","first-page":"1","volume":"33","author":"HC Maltezou","year":"2009","unstructured":"Maltezou HC: Metallo-\u03b2-lactamases in Gram-Negative Bacteria: Introducing The Era of Pan-Resistance. Int J Antimicrob Agents. 2009, 33 (405): 1-40. e7","journal-title":"Int J Antimicrob Agents"},{"key":"4207_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jinf.2008.06.001","volume":"57","author":"DA Goff","year":"2008","unstructured":"Goff DA, Mangino JE: Ertapenem: No Effect on Aerobic Gram-Negative Susceptibilities to Imipenem. Journal of Infection. 2008, 57: 123-127. 10.1016\/j.jinf.2008.06.001.","journal-title":"Journal of Infection"},{"key":"4207_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/jac\/dks385","volume":"68","author":"DAJ McDougall","year":"2013","unstructured":"McDougall DAJ, Mortan AP, Playford EG: Association of Ertapenem and Antipseudomonal Carbapenem Usage and Carbapenem Resistance in Pseudomonas aeruginosa Among 12 Hospitals in Queensland, Australia. Journal of Antimicrobial Chemotherapy. 2013, 68: 457-460. 10.1093\/jac\/dks385.","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"5","key":"4207_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1086\/652154","volume":"31","author":"KJ Eagye","year":"2010","unstructured":"Eagye KJ: MPH, Nicolau D P: Absence of Association Between Use of Ertapenem and Change in Antipseudomonal Carbapenem Susceptibility Rates In 25 Hospitals. Infect Control Hosp Epidemiol. 2010, 31 (5): 485-90. 10.1086\/652154.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"12","key":"4207_CR10","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1128\/AAC.00064-09","volume":"53","author":"EJC Goldstein","year":"2009","unstructured":"Goldstein EJC, Citron DM, Peraino V, Elgourt T, Meibohm AR, Lu S: Introduction of Ertapenem Into a Hospital Formulary: Effect On Antimicrobial Usage and Improved In Vitro Susceptibility of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009, 53 (12): 5122-5126. 10.1128\/AAC.00064-09.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"4207_CR11","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1128\/jcm.35.8.2061-2067.1997","volume":"35","author":"CL Emery","year":"1997","unstructured":"Emery CL, Weymouth LA: Detection and Clinical Significance of Extended-spectrum Beta-lactamases in A Tertiary-care Medical Center. J Clin Microbiol. 1997, 35 (8): 2061-2067.","journal-title":"J Clin Microbiol"},{"issue":"1","key":"4207_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH: Prediction of Creatinine Clearance from Serum Creatinine. Nephron. 1976, 16 (1): 31-41. 10.1159\/000180580.","journal-title":"Nephron"},{"key":"4207_CR13","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/jac\/dki093","volume":"55","author":"PMG Filius","year":"2005","unstructured":"Filius PMG, Liem TBY, van der Linden PD, Janknegt R, Natsch S, Vulto AG, Verbrugh HA: An additional measure for quantifying antibiotic use in hospitals. Journal of Antimicrobial Chemotherapy. 2005, 55: 805-808. 10.1093\/jac\/dki093.","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"4207_CR14","volume-title":"Guidelines For ATC Classification and DDD Assignment 2010","author":"WHO Collaborating Centre for Drug Statistics Methodology (Norway)","year":"2010","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology (Norway): Guidelines For ATC Classification and DDD Assignment 2010. 2010, Oslo, Norway: WHO Collaborating Centre"},{"key":"4207_CR15","volume-title":"Network for Antimicrobial Resistance Surveillance (Singapore) Version 1.0. Antimicrobial Resistance Report: July to December 2008","author":"TH Koh","year":"2008","unstructured":"Koh TH, Jureen R, Tan TY, Hsu LY, Krishnan P, Tee N: Network for Antimicrobial Resistance Surveillance (Singapore) Version 1.0. Antimicrobial Resistance Report: July to December 2008. 2008, Unpublished Data"},{"key":"4207_CR16","volume-title":"Network for Antimicrobial Resistance Surveillance (Singapore) Version 1.2. Antimicrobial Utilization Report","author":"TH Koh","year":"2009","unstructured":"Koh TH, Jureen R, Tan TY, Chiew YF, Hsu LY, Krishnan P, Tee N: Network for Antimicrobial Resistance Surveillance (Singapore) Version 1.2. Antimicrobial Utilization Report. 2009, July to December 2009. Unpublished Data"},{"key":"4207_CR17","volume-title":"Network for Antimicrobial Resistance Surveillance (Singapore) 2011. Carbapenem-Resistant Pseudomonas Aeruginosa","author":"TH Koh","year":"2011","unstructured":"Koh TH, Tan TY, Jureen R, Hsu LY, Krishnan P, Tee N, Chan J: Network for Antimicrobial Resistance Surveillance (Singapore) 2011. Carbapenem-Resistant Pseudomonas Aeruginosa. 2011, 2006\u20132010. Unpublished Data"},{"key":"4207_CR18","volume-title":"Network for Antimicrobial Resistance Surveillance (Singapore) 2011. Carbapenem-Resistant Acinetobacter","author":"TH Koh","year":"2011","unstructured":"Koh TH, Tan TY, Jureen R, Hsu LY, Krishnan P, Tee N, Chan J: Network for Antimicrobial Resistance Surveillance (Singapore) 2011. Carbapenem-Resistant Acinetobacter. 2011, 2006\u20132010. Unpublished Data"},{"key":"4207_CR19","volume-title":"Network for Antimicrobial Resistance Surveillance (Singapore). Klebsiella pneumoniae 2011","author":"TH Koh","year":"2011","unstructured":"Koh TH, Tan TY, Jureen R, Hsu LY, Krishnan P, Tee N, Chan J: Network for Antimicrobial Resistance Surveillance (Singapore). Klebsiella pneumoniae 2011. 2011, 2006\u20132010. Unpublished Data"},{"key":"4207_CR20","volume-title":"Network for Antimicrobial Resistance Surveillance (Singapore). Escherichia coli 2011","author":"TH Koh","year":"2011","unstructured":"Koh TH, Tan TY, Jureen R, Hsu LY, Krishnan P, Tee N, Chan J: Network for Antimicrobial Resistance Surveillance (Singapore). Escherichia coli 2011. 2011, 2006\u20132010. Unpublished Data"},{"key":"4207_CR21","volume-title":"Network for Antimicrobial Resistance Surveillance (Singapore). Klebsiella pneumoniae:","author":"TH Koh","year":"2006","unstructured":"Koh TH, Tan TY, Jureen R, Hsu LY, Krishnan P, Tee N, Chan J: Network for Antimicrobial Resistance Surveillance (Singapore). Klebsiella pneumoniae:. 2006, Unpublished Data, \u20132010"},{"issue":"4","key":"4207_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2710.2007.00836.x","volume":"32","author":"K Urb\u00e1nek","year":"2007","unstructured":"Urb\u00e1nek K, Kol\u00e1r M, Loveckov\u00e1 Y, Strojil J, Santav\u00e1 L: Influence of Third-Generation Cephalosporin Utilization on the Occurrence of ESBL-positive Klebsiella pneumoniae Strains. J Clin Pharm Ther. 2007, 32 (4): 403-8. 10.1111\/j.1365-2710.2007.00836.x.","journal-title":"J Clin Pharm Ther"},{"key":"4207_CR23","first-page":"623","volume-title":"Drug Information Handbook","author":"CF Lacy","year":"2011","unstructured":"Lacy CF, Armstrong LL, Goldman MP, Lance LL: Drug Information Handbook. 2011, Hudson, Ohio: Lexi-Comp, Inc, 623-4. 20","edition":"20"},{"key":"4207_CR24","first-page":"831","volume":"37","author":"DC Lye","year":"2008","unstructured":"Lye DC, Wijaya L, Chan J, Teng CP, Leo YS: Ertapenem for Treatment of Extended-Spectrum Beta-lactamase-producing Multidrug-resistant Gram-Negative Bacteremia. Annals Academy of Medicine. 2008, 37: 831-4.","journal-title":"Annals Academy of Medicine"},{"issue":"1","key":"4207_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.diagmicrobio.2010.12.008","volume":"70","author":"NY Lee","year":"2011","unstructured":"Lee NY, Huang WH, Tsui KC, Hsueh PR, Ko WC: Carbapenem Therapy for Bacteremia Due to Extended-spectrum Beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae. Diagnostic Microbiology & Infectious Disease. 2011, 70 (1): 150-3. 10.1016\/j.diagmicrobio.2010.12.008.","journal-title":"Diagnostic Microbiology & Infectious Disease"},{"issue":"1","key":"4207_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ijid.2011.09.019","volume":"16","author":"UI Wu","year":"2012","unstructured":"Wu UI, Chen WC, Yang CS, Wang JL, Hu FC, Chang SC, Chen YC: Ertapenem in the Treatment of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing Escherichia coli: A Propensity Score Analysis. Int J Infect Dis. 2012, 16 (1): 47-52. 10.1016\/j.ijid.2011.09.019.","journal-title":"Int J Infect Dis"},{"issue":"4","key":"4207_CR27","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1128\/JCM.00651-08","volume":"47","author":"A Leavitt","year":"2009","unstructured":"Leavitt A, Chmelnitsky I, Colodner R, Ofek I, Carmeli Y, Navon-Venezia S: Ertapenem Resistance Among Extended-Spectrum-Beta-Lactamase-Producing Klebsiella pneumoniae. J Clin Microbiol. 2009, 47 (4): 969-74. 10.1128\/JCM.00651-08.","journal-title":"J Clin Microbiol"},{"issue":"2","key":"4207_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1590\/S1413-86702008000200001","volume":"12","author":"ALLM Lima","year":"2008","unstructured":"Lima ALLM, Oliveria PRD, Paula AP, Zumiotti AV: Influence of Ertapenem Administration On the Incidence of Carbapenem-Resistant Pseudomonas Aeruginosa. Brazilian Journal of Infectious Diseases. 2008, 12 (2): 105-106.","journal-title":"Brazilian Journal of Infectious Diseases"},{"key":"4207_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jhin.2006.04.015","volume":"64","author":"ME Falagas","year":"2006","unstructured":"Falagas ME, Kopterides P: Risk Factors For the Isolation of Multi-Drug-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa: A Systematic Review of the Literature. Journal of Hospital Infection. 2006, 64: 7-15. 10.1016\/j.jhin.2006.04.015.","journal-title":"Journal of Hospital Infection"},{"key":"4207_CR30","volume-title":"Prevalence and Predictors of Methicillin-resistant Staphylococcus aureus (MRSA) and Extended-spectrum Beta-lactamase (ESBL) Gram-negative Bacteria at Hospital Presentation in Singapore, abstr. 69.009","author":"S Pada","year":"2008","unstructured":"Pada S, Lye DC, Krishnan P, Leo YS: Prevalence and Predictors of Methicillin-resistant Staphylococcus aureus (MRSA) and Extended-spectrum Beta-lactamase (ESBL) Gram-negative Bacteria at Hospital Presentation in Singapore, abstr. 69.009. 2008, Kuala Lumpur, Malaysia: 13th International Congress on Infectious Dieases 2008"},{"issue":"3","key":"4207_CR31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ijantimicag.2009.11.012","volume":"35","author":"J Collazose","year":"2010","unstructured":"Collazose J, Asensi V, Cartona JA, JFierer D, EBustillo C, Rodriguez-Guardadoa A, Suarez-Zarracinaa T, Asensib JM, Saavedraa A, Martin-Canala G: Meropenem Monotherapy is as Effective as and Safer than Imipenem to Treat Brain Abscesses. Int J Antimicrob Agents. 2010, 35 (3): 301-4. 10.1016\/j.ijantimicag.2009.11.012.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"4207_CR32","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2165\/00002018-200730080-00002","volume":"30","author":"L Peter","year":"2007","unstructured":"Peter L: Safety Profile of Meropenem: An Updated Review of Over 6000 Patients Treated with Meropenem. Drug Saf. 2007, 30 (8): 657-668. 10.2165\/00002018-200730080-00002.","journal-title":"Drug Saf"},{"issue":"6","key":"4207_CR33","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2165\/00003495-200868060-00006","volume":"68","author":"MB Claudine","year":"2008","unstructured":"Claudine MB, Katherine A, Susan JK, Lyseng-Williamson : Meropenem: A Review of its Use in the Treatment of Serious Bacterial Infections. Drugs. 2008, 68 (6): 803-838. 10.2165\/00003495-200868060-00006.","journal-title":"Drugs"},{"issue":"2","key":"4207_CR34","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.diagmicrobio.2009.08.019","volume":"66","author":"TY Tan","year":"2010","unstructured":"Tan TY, Ng LS, He J, Hsu LY: CTX-M and AmpC Beta-lactamases Contributing to Increased Prevalence of Ceftriaxone-resistant Escherichia coli in Changi General Hospital, Singapore. Diagn Microbiol Infect Dis. 2010, 66 (2): 210-3. 10.1016\/j.diagmicrobio.2009.08.019.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"4207_CR35","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/BF01704610","volume":"20","author":"A Bauernfeind","year":"1992","unstructured":"Bauernfeind A, Casellas JM, Goldberg M, Holley M, Junwirth R, Mangold P, Rohnisch T, Schweighart S, Wilhelm R: A New Plasmidic Cefotaximase from Patients Infected with Salmonella typhimurium. Infection. 1992, 20: 158-63. 10.1007\/BF01704610.","journal-title":"Infection"},{"key":"4207_CR36","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/jac\/44.4.489","volume":"44","author":"A Palucha","year":"1999","unstructured":"Palucha A, Mikiewicz B, Hryniewicz W, Gniadkowski M: Concurrent Outbreaks of Extended-spectrum Beta-lactamase-producing Organisms of the Family Enterobacteriaceae in a Warsaw Hospital. Journal of Antimicrobial Chemotherapy. 1999, 44: 489-99. 10.1093\/jac\/44.4.489.","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"4207_CR37","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1128\/JCM.37.12.4167-4169.1999","volume":"37","author":"D Szabo","year":"1999","unstructured":"Szabo D, Filetoth Z, Szentandrassy J, Nemedi M, Toth E, Jeney C, Kispal G, Rozgonyi F: Molecular Epidemiology of A Cluster of Cases due to Klebsiella pneumoniae producing SHV-5 Extended-spectrum \u00df-lactamase in the Premature Intensive Care Unit of a Hungarian Hospital. J Clin Microbiol. 1999, 37: 4167-9.","journal-title":"J Clin Microbiol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-523.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-13-523\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-523.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T20:05:37Z","timestamp":1630613137000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-13-523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,6]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["4207"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-13-523","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,6]]},"assertion":[{"value":"12 June 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"523"}}